Nucleate Boston partners with the Massachusetts Life Science Center to support the formation of early-stage biotech ventures

Today, the Nucleate Boston chapter is proud to announce its partnership with the Massachusetts Life Sciences Center (MLSC). As a Platinum level regional partner, the MLSC will provide funding totaling...

Read More

MLSC Launches 2022-2023 Women’s Health Programming Round

The MLSC is excited to launch the next round of programming for its Women’s Health Initiative: First Look Awards, Innovation Grants, and Collaboration program. The deadline to apply for the 2022-2023 program...

Read More

AOA Dx Closes $7 Million Funding Round To Bring The First Accurate Early Detection Test For Ovarian Cancer To Market

AOA Dx Inc announced today that they have closed a $7 million funding round led by Avestria Ventures, AlleyCorp, The Helm, RH Capital, Olive Tree Capital, Tencent, and other notable investors....

Read More

Baker-Polito Administration Announces $14.6 Million to Support Life Sciences Workforce Development and STEM Education

39 awards will support new and expanded STEM curricula at 40 schools and enhance and expand industry-aligned training programs at 22 institutions; 25,000+ students will receive enhanced training and education...

Read More

MLSC Launches 2022-2023 Capital Programming Round

The MLSC is excited to launch the next round of capital programs for: Bits to Bytes, Novel Therapeutics Delivery, and Research Infrastructure. The deadline to apply for the 2022-2023 program year is November...

Read More

Immunology startup GentiBio signs $1.9B deal with Bristol Myers

At just two years old, immunology startup GentiBio has signed a collaboration deal with a major pharmaceutical company that could be worth up to $1.9 billion. Bristol Myers Squibb Co....

Read More

Lilly takes long view on Alzheimer’s drug as FDA starts expedited review

The Food and Drug Administration has agreed to an expedited review of Eli Lilly’s experimental Alzheimer’s disease medicine donanemab. Donanemab is one of several drugs in late-stage clinical testing that...

Read More

Ginkgo Bioworks buys Zymergen for $300 million

Boston-based Ginkgo Bioworks has agreed to buy Zymergen, a biotech firm whose value plunged four months after going public, in an all-stock deal, the companies said Monday. The transaction values...

Read More